e-Therapeutics Begins Phase I Study of Oral Formulation of Anti-Cancer Compound ETS2101 with Healthy Volunteers by EON

VIEWS: 3 PAGES: 2

OXFORD & NEWCASTLE, England--(BUSINESS WIRE)--e-Therapeutics doses the first healthy volunteer in a new Phase I clinical trial with an oral formulation of its anti-cancer compound ETS2101 to evaluate the PK and bioavailability of the oral drug.

More Info
									
								
To top